Cargando…
Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies
Anticoagulant therapy is a major component in the management of acute coronary syndromes (ACS). Four anticoagulant agents are currently commercially available for ACS, namely unfractionated heparin (UFH), enoxaparin, bivalirudin and fondaparinux. We describe the advantages of fondaparinux and the re...
Autor principal: | Schiele, François |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856573/ https://www.ncbi.nlm.nih.gov/pubmed/20407625 |
Ejemplares similares
-
Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5)
por: Alfonso Ross Terres, Jorge, et al.
Publicado: (2015) -
Management of acute coronary syndromes with fondaparinux
por: Wienbergen, Harm, et al.
Publicado: (2007) -
Fondaparinux: A cornerstone drug in acute coronary syndromes
por: Khan, Mohammed Yunus, et al.
Publicado: (2022) -
The Fondaparinux Paradox: Fondaparinux-Related Heparin-induced Thrombocytopenia
por: Vadi, Sonali, et al.
Publicado: (2018) -
Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for
Acute Coronary Syndrome? - Brazilian Registry Data
por: Soeiro, Alexandre de Matos, et al.
Publicado: (2016)